Literature DB >> 19904208

Lower urinary tract symptoms, obesity and the metabolic syndrome.

Samdeep Moul1, Kevin T McVary.   

Abstract

PURPOSE OF REVIEW: The epidemic of obesity and concomitant metabolic syndrome is well documented. New evidence points to a connection between the components of metabolic syndrome and benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). RECENT
FINDINGS: Multiple studies have demonstrated a strong independent association between the components of metabolic syndrome and BPH/LUTS. Furthermore, modifiable risk factors, such as increased physical activity, appear to decrease the risk of BPH/LUTS.
SUMMARY: Emerging data points to a strong relationship between metabolic syndrome and BPH/LUTS, indicating a common cause. Further exploration of this relationship may result in a new understanding of the pathophysiology, treatment, and prevention of these disorders.

Entities:  

Mesh:

Year:  2010        PMID: 19904208     DOI: 10.1097/MOU.0b013e3283336f3f

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  24 in total

Review 1.  [Primary and secondary prevention of benign prostatic hyperplasia: current knowledge and implications for clinical management].

Authors:  M Oelke; S Madersbacher
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

Review 2.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

3.  Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study.

Authors:  Selçuk Altın; Tunç Ozan; Selçuk İlhan; Nevin İlhan; Rahmi Onur
Journal:  Turk J Urol       Date:  2015-09

Review 4.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

Review 5.  Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.

Authors:  Osamu Yokoyama; Yasuhiko Igawa; Masayuki Takeda; Takafumi Yamaguchi; Masahiro Murakami; Lars Viktrup
Journal:  Ther Adv Urol       Date:  2015-10

Review 6.  Path of translational discovery of urological complications of obesity and diabetes.

Authors:  Firouz Daneshgari; Guiming Liu; Ann T Hanna-Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-04

7.  NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance.

Authors:  David C Austin; Douglas W Strand; Harold L Love; Omar E Franco; Magdalena M Grabowska; Nicole L Miller; Omar Hameed; Peter E Clark; Robert J Matusik; Ren J Jin; Simon W Hayward
Journal:  Prostate       Date:  2016-05-16       Impact factor: 4.104

8.  Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model.

Authors:  Qiqi He; Melissa A Babcook; Sanjeev Shukla; Eswar Shankar; Zhiping Wang; Guiming Liu; Bernadette O Erokwu; Chris A Flask; Lan Lu; Firouz Daneshgari; Gregory T MacLennan; Sanjay Gupta
Journal:  Prostate       Date:  2016-04-04       Impact factor: 4.104

9.  Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.

Authors:  Luiz O Leiria; Carolina Sollon; Marina C Calixto; Letícia Lintomen; Fabíola Z Mónica; Gabriel F Anhê; Gilberto De Nucci; Angelina Zanesco; Andrew D Grant; Edson Antunes
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Insulin relaxes bladder via PI3K/AKT/eNOS pathway activation in mucosa: unfolded protein response-dependent insulin resistance as a cause of obesity-associated overactive bladder.

Authors:  Luiz O Leiria; Carolina Sollon; Fernando R Báu; Fabíola Z Mónica; Carlos L D'Ancona; Gilberto De Nucci; Andrew D Grant; Gabriel F Anhê; Edson Antunes
Journal:  J Physiol       Date:  2013-03-11       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.